| 2024-10-19 | Types of collagen - Part 2 | 0:00 | 0 | |
|
| 2024-10-19 | Drug and prodrug | 0:00 | 1 | |
|
| 2024-10-19 | Vitamin D | 0:00 | 0 | |
|
| 2024-10-19 | Types of collagen | 0:00 | 0 | |
|
| 2024-10-19 | Biliary excretion | 0:00 | 1 | |
|
| 2024-10-19 | Pulmonary excretion | 0:00 | 1 | |
|
| 2024-10-19 | Receptor binding - part 1 | 0:00 | 1 | |
|
| 2024-10-19 | Arteries of anterior cranial fossa | 0:00 | 0 | |
|
| 2024-10-19 | Lymphatic drainage of pelvic structures | 0:00 | 2 | |
|
| 2024-10-19 | Factors inhibiting insulin secretion | 0:00 | 0 | |
|
| 2024-10-19 | Types of enzyme inducers | 0:00 | 0 | |
|
| 2024-10-19 | CYP 1a | 0:00 | 1 | |
|
| 2024-10-19 | Tissue stem cells and location - part 1 | 0:00 | 2 | |
|
| 2024-10-19 | Drugs and prodrugs - part 2 | 0:00 | 0 | |
|
| 2024-10-19 | Regulation of growth hormone secretion | 0:00 | 0 | |
|
| 2024-10-19 | Non dialyzable drugs | 0:00 | 1 | |
|
| 2024-10-19 | SGLT and GLUT transporter | 0:00 | 0 | |
|
| 2024-10-17 | Schedule of drugs | 0:00 | 0 | |
|
| 2024-10-17 | Renal excretion | 0:00 | 1 | |
|
| 2024-10-17 | Phase 2 reactions | 0:00 | 0 | |
|
| 2024-10-17 | Dialyzable drugs - part 1 | 0:00 | 2 | |
|
| 2024-10-17 | Tmax | 0:00 | 1 | |
|
| 2024-10-17 | Phase 1 reaction - Part 2 | 0:00 | 0 | |
|
| 2024-10-17 | Cytochrome p450 | 0:00 | 0 | |
|
| 2024-10-17 | Dialyzable drugs - Part 2 | 0:00 | 3 | |
|
| 2024-10-17 | Phase 1 reaction - drug metabolism | 0:00 | 0 | |
|
| 2024-10-17 | Schedule of drugs - part 2 | 0:00 | 0 | |
|
| 2024-10-17 | Drugs and prodrugs - part 2 | 0:00 | 1 | |
|
| 2024-10-16 | Drug elimination - Biotransformation | 0:00 | 1 | |
|
| 2024-10-16 | Apparent volume of distribution | 0:00 | 0 | |
|
| 2024-10-16 | Sympathetic nervous system | 0:00 | 0 | |
|
| 2024-10-16 | Enzymatic receptors | 0:00 | 1 | |
|
| 2024-10-16 | Drug effect modifications - part 3 | 0:00 | 0 | |
|
| 2024-10-16 | Cmax and AUC | 0:00 | 1 | |
|
| 2024-10-16 | Type of enzyme inducers - part 2 | 0:00 | 4 | |
|
| 2024-10-16 | BPH - Benign prostatic hyperplasia - surgical management | 0:00 | 3 | |
|
| 2024-10-16 | Nuclear receptors | 0:00 | 1 | |
|
| 2024-10-16 | Pulmonary excretion | 0:00 | 1 | |
|
| 2024-10-16 | Drug effect modulations - part 1 | 0:00 | 1 | |
|
| 2024-10-16 | Anti obesity drugs - Part 3 | 0:00 | 0 | |
|
| 2024-10-16 | Apparent volume of distribution | 0:00 | 0 | |
|
| 2024-10-16 | Anti obesity drugs - part 2 | 0:00 | 0 | |
|
| 2024-10-16 | Urine ph and drug elimination - part 2 | 0:00 | 3 | |
|
| 2024-10-16 | Biliary excretion | 0:00 | 3 | |
|
| 2024-10-16 | Ligand gated ion channel | 0:00 | 0 | |
|
| 2024-10-16 | Types of enzymes inducers | 0:00 | 0 | |
|
| 2024-10-16 | Biotransformation | 0:00 | 1 | |
|
| 2024-10-16 | G protein coupled receptor | 0:00 | 0 | |
|
| 2024-10-16 | Human teratogenic drugs | 0:00 | 0 | |
|
| 2024-10-16 | Drugs and pro drugs | 0:00 | 1 | |
|
| 2024-10-16 | Non dialyzable drugs | 0:00 | 2 | |
|
| 2024-10-16 | Drug effect modulations - part 2 | 0:00 | 1 | |
|
| 2024-10-15 | Alpha 1 receptors | 0:00 | 1 | |
|
| 2024-10-15 | Phase 1 reactions - part 2 | 0:00 | 0 | |
|
| 2024-10-15 | Urine ph and elimination - part 1 | 0:00 | 0 | |
|
| 2024-10-15 | Botulinum toxin | 0:00 | 0 | |
|
| 2024-10-15 | Therapeutic index - Part 1 | 0:00 | 0 | |
|
| 2024-10-15 | Fixed dose combination | 0:00 | 1 | |
|
| 2024-10-15 | Nicotinic receptors | 0:00 | 0 | |
|
| 2024-10-15 | Fixed dose combination - part 2 | 0:00 | 1 | |
|
| 2024-10-15 | Therapeutic index - part 3 | 0:00 | 1 | |
|
| 2024-10-15 | Alpha 2 receptors | 0:00 | 0 | |
|
| 2024-10-15 | Anti obesity drugs - Part 1 | 0:00 | 0 | |
|
| 2024-10-15 | Receptor binding - part 2 | 0:00 | 0 | |
|
| 2024-10-15 | CYP 2d6 | 0:00 | 1 | |
|
| 2024-10-15 | Beta blockers - Types | 0:00 | 0 | |
|
| 2024-10-15 | Parasympathetic nervous system | 0:00 | 0 | |
|
| 2024-10-15 | Therapeutic index - part 2 | 0:00 | 2 | |
|
| 2024-10-15 | Cytochrome p450 interactions | 0:00 | 1 | |
|
| 2024-10-15 | CYP 3a4 | 0:00 | 1 | |
|
| 2024-10-15 | Anaphylaxis and management | 0:00 | 0 | |
|
| 2024-10-15 | Human teratogenic drugs - part 2 | 0:00 | 0 | |
|
| 2024-10-15 | Receptor binding | 0:00 | 2 | |
|
| 2024-10-15 | Receptor binding - part 3 | 0:00 | 1 | |
|
| 2024-10-15 | Myasthenia gravis - drugs | 0:00 | 0 | |
|
| 2024-10-15 | BPH - Benign prostatic hyperplasia treatment | 0:00 | 0 | |
|
| 2024-10-14 | Diuretics - Excretion of electrolytes | 0:00 | 0 | |
|
| 2024-10-14 | Hypertrophic cardiomyopathy | 0:00 | 0 | |
|
| 2024-10-14 | Phase 2 reactions - part 2 | 0:00 | 0 | |
|
| 2024-10-14 | CYP 2d6 | 0:00 | 0 | |
|
| 2024-10-14 | Volume of distribution - part 2 | 0:00 | 2 | |
|
| 2024-10-14 | Renal tubular acidosis | 0:00 | 1 | |
|
| 2024-10-14 | Fixed dose combination | 0:00 | 0 | |
|
| 2024-10-14 | Apparent volume of distribution | 0:00 | 1 | |
|
| 2024-10-14 | Muscarinic receptors | 0:00 | 0 | |
|
| 2024-10-14 | Anti obesity drugs - Part 1 | 0:00 | 4 | |
|
| 2024-10-14 | Phase 1 reaction - Durg metabolism | 0:00 | 1 | |
|
| 2024-10-14 | CYP 1a | 0:00 | 0 | |
|
| 2024-10-14 | Human teratogenic drugs - part 2 | 0:00 | 0 | |
|
| 2024-10-14 | Military shadow in chest Xray | 0:00 | 0 | |
|
| 2024-10-14 | Color of urine in diseases | 0:00 | 0 | |
|
| 2024-10-14 | Schedules of drugs - part 2 | 0:00 | 1 | |
|
| 2024-10-14 | Pulmonary arterial hypertension - PAH | 0:00 | 1 | |
|
| 2024-10-14 | CYP 2c8 and 2c9 | 0:00 | 2 | |
|
| 2024-10-14 | ECG leads | 0:00 | 0 | |
|
| 2024-10-14 | G protein coupled receptors | 0:00 | 1 | |
|
| 2024-10-14 | Hypertension classification | 0:00 | 0 | |
|
| 2024-10-14 | Glomerular diseases - sites of deposits | 0:00 | 0 | |
|
| 2024-10-14 | Glomerulopathies - commons | 0:00 | 0 | |
|
| 2024-10-14 | Phase 2 reactions | 0:00 | 2 | |
|
